Do Pharmaceutical Mergers Harm Drug Innovation? / Aus der Reihe: e-fellows.net stipendiaten-wissen Bd.Band 1197 (ePub)
(Sprache: Englisch)
Master's Thesis from the year 2013 in the subject Business economics - Miscellaneous, grade: 8,5 (NL, äquivalent zu 1,2), Utrecht University (Law, Economics and Governance), course: Mergers & Akquisitions, language: English, abstract: The number and volume...
sofort als Download lieferbar
eBook (ePub)
18.99 €
- Lastschrift, Kreditkarte, Paypal, Rechnung
- Kostenloser tolino webreader
Produktdetails
Produktinformationen zu „Do Pharmaceutical Mergers Harm Drug Innovation? / Aus der Reihe: e-fellows.net stipendiaten-wissen Bd.Band 1197 (ePub)“
Master's Thesis from the year 2013 in the subject Business economics - Miscellaneous, grade: 8,5 (NL, äquivalent zu 1,2), Utrecht University (Law, Economics and Governance), course: Mergers & Akquisitions, language: English, abstract: The number and volume of pharmaceutical companies' mergers and acquisitions have reached exorbitant magnitudes in the last decade, with estimations of over 1,300 deals worth US$ 690 billion between 2000 and 2009.1 The biggest transaction, valued at US$ 66.7 billion2, occurred in 2009 when Pfizer bought Wyeth. The sheer dimension of transactions in this sector, being subject to significant public interest, poses questions about the motivations behind these deals, which are mostly believed to be countermeasures for patent expirations, as well as the impact on drug innovation.
Even though, the regular object of interest regarding mergers is the shareholder value, in this specific case drug innovation is of particular interest as it does not only influence the future prospects of the pharmaceutical companies but also long term public health. Hence, the objective of this thesis is to discover what the impact of pharmaceutical mergers on R&D intensity and efficiency of the acquiring organization and on the pharmaceutical industry as a whole is.
Even though, the regular object of interest regarding mergers is the shareholder value, in this specific case drug innovation is of particular interest as it does not only influence the future prospects of the pharmaceutical companies but also long term public health. Hence, the objective of this thesis is to discover what the impact of pharmaceutical mergers on R&D intensity and efficiency of the acquiring organization and on the pharmaceutical industry as a whole is.
Bibliographische Angaben
- Autor: Jan Schmidt
- 2015, 1. Auflage, 49 Seiten, Englisch
- Verlag: GRIN Verlag
- ISBN-10: 3656962162
- ISBN-13: 9783656962168
- Erscheinungsdatum: 15.05.2015
Abhängig von Bildschirmgröße und eingestellter Schriftgröße kann die Seitenzahl auf Ihrem Lesegerät variieren.
eBook Informationen
- Dateiformat: ePub
- Größe: 0.89 MB
- Ohne Kopierschutz
- Vorlesefunktion
Sprache:
Englisch
Kommentar zu "Do Pharmaceutical Mergers Harm Drug Innovation? / Aus der Reihe: e-fellows.net stipendiaten-wissen Bd.Band 1197"
0 Gebrauchte Artikel zu „Do Pharmaceutical Mergers Harm Drug Innovation? / Aus der Reihe: e-fellows.net stipendiaten-wissen Bd.Band 1197“
Zustand | Preis | Porto | Zahlung | Verkäufer | Rating |
---|
Schreiben Sie einen Kommentar zu "Do Pharmaceutical Mergers Harm Drug Innovation? / Aus der Reihe: e-fellows.net stipendiaten-wissen Bd.Band 1197".
Kommentar verfassen